OPKO Health (NASDAQ:OPK – Get Free Report) and Zicix (OTCMKTS:ZICXD – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.
Risk & Volatility
OPKO Health has a beta of 1.51, meaning that its stock price is 51% more volatile than the S&P 500. Comparatively, Zicix has a beta of 0.53, meaning that its stock price is 47% less volatile than the S&P 500.
Insider and Institutional Ownership
64.6% of OPKO Health shares are owned by institutional investors. 44.7% of OPKO Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| OPKO Health | $587.90 million | 1.71 | -$225.68 million | ($0.09) | -15.00 |
| Zicix | N/A | N/A | N/A | ($100.14) | -0.00 |
Zicix has lower revenue, but higher earnings than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Zicix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares OPKO Health and Zicix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| OPKO Health | -12.40% | -5.88% | -3.83% |
| Zicix | N/A | N/A | N/A |
Analyst Recommendations
This is a summary of current ratings for OPKO Health and Zicix, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| OPKO Health | 1 | 4 | 1 | 0 | 2.00 |
| Zicix | 0 | 0 | 0 | 0 | 0.00 |
OPKO Health presently has a consensus target price of $1.55, indicating a potential upside of 14.81%. Given OPKO Health’s stronger consensus rating and higher possible upside, equities analysts plainly believe OPKO Health is more favorable than Zicix.
Summary
OPKO Health beats Zicix on 8 of the 12 factors compared between the two stocks.
About OPKO Health
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.
About Zicix
Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.
Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.
